Sarepta Therapeutics Names Sandy Mahatme Senior Vice President,

Sarepta Therapeutics Names Sandy Mahatme Senior Vice President, Chief
Financial Officer and Ty Howton Senior Vice President, General
CAMBRIDGE, MA -- (Marketwire) -- 11/05/12 --  Sarepta Therapeutics,
Inc. (NASDAQ: SRPT), a developer of innovative RNA-based
therapeutics, announced the appointment of Sandesh "Sandy" Mahatme,
senior vice president, chief financial officer, and David Tyronne
"Ty" Howton, senior vice president, general counsel, effective today. 
"Both Sandy and Ty bring a considerable breadth of experience to
Sarepta gained from their senior roles at industry-leading biotechs,"
said Chris Garabedian, Sarepta's president and CEO. "They provide
tremendous strength to Sarepta's executive team in dealing with the
financial, legal, and corporate development activities associated
with a growth biotech company as we bring eteplirsen through
late-stage development and commercialization." 
Mr. Mahatme joins Sarepta from Celgene Corporation where he served in
various roles including senior vice president of Corporate
Development, Corporate Treasurer and senior vice president of Tax
since 2006. While at Celgene, Mr. Mahatme was instrumental in
building Celgene's Treasury and Tax functions before establishing the
Corporate Development department, focused on strategic, targeted
initiatives including emerging markets, acquisitions and licensing
and strategic planning. Prior to Celgene, Mr. Mahatme worked for
Pfizer Inc. for eight and a half years in senior roles in Business
Development and Corporate Tax. Mr. Mahatme started his career at
Ernst & Young where he advised multinational corporations on a broad
range of transactions. Mr. Mahatme holds Master of Laws (LL.M)
degrees from Cornell Law School and NYU School of Law and is a member
of the New York State Bar Association. 
Mr. Mahatme commented, "Sarepta has great potential to build a
successful independent biotech company on the strength of eteplirsen
for Duchenne muscular dystrophy and I will be focused on ensuring
that the company is well positioned financially to advance the
program forward."  
Mr. Howton joins Sarepta from Vertex Pharmaceuticals where he was the
senior vice president, chief legal officer and a member of the
executive team. In that capacity, Mr. Howton participated in the
general management of the company and oversaw all aspects of the
Vertex global legal and compliance departments. Prior to his
appointment as chief legal officer in 2011, Mr. Howton served as the
chief compliance officer and was responsible for designing and
implementing the Vertex corporate compliance program as well as
chairing the company's Corporate Compliance Committee. Mr. Howton
joined Vertex in 2009 from Genentech where he served in a number of
legal roles before becoming the company's chief healthcare compliance
officer. Prior to joining Genentech Inc. in 2003, Mr. Howton was a
member of the Sidley Austin LLP corporate healthcare practice where
he advised on corporate transactions involving life science companies
and provided regulatory counsel. Mr. Howton holds a B.A. from Yale
University and a J.D. from Northwestern University School of Law.  
Mr. Howton commented, "I'm excited to become a part of the Sarepta
management team and to prepare the company for further success with
its proprietary RNA technology platform. There is the potential to
build a pipeline of additional products and to facilitate
partnerships across a variety of disease areas."  
About Sarepta Therapeutics  
Sarepta Therapeutics is focused on developing first-in-class
RNA-based therapeutics to improve and save the lives of people
affected by serious and life-threatening rare and infectious
diseases. Sarepta's diverse pipeline includes its lead program
eteplirsen, for Duchenne muscular dystrophy, as well as potential
treatments for some of the world's most lethal infectious diseases.
Sarepta aims to build a leading, independent biotech company
dedicated to translating its RNA-based science into transformational
therapeutics for patients who face significant unmet medical needs.
For more information, please visit us at 
Forward-Looking Statements and Information  
In order to provide Sarepta's investors with an understanding of its
current results and future prospects, this press release contains
statements that are forward-looking. Any statements contained in this
press release that are not statements of historical fact may be
deemed to be forward-looking statements. Words such as "believes,"
"anticipates," "plans," "expects," "will," "intends," "potential,"
"possible" and similar expressions are intended to identify
forward-looking statements. These forward-looking statements include
statements about the development of Sarepta's product candidates, the
expected timing of results from the extension study of eteplirsen,
the potential for the creation of novel dystrophin to lead to
clinically meaningful benefits over a longer course of treatment with
eteplirsen and Sarepta's estimates regarding its future revenue and
expenses and expectations regarding future success, revenue and
funding from government and other sources.  
These forward-looking statements involve risks and uncertainties,
many of which are beyond Sarepta's control. Known risk factors
include, among others: clinical trials may not demonstrate safety and
efficacy of any of Sarepta's drug candidates and/or Sarepta's
antisense-based technology platform; development of any of Sarepta's
drug candidates may not result in funding from the U.S. government in
the anticipated amounts or on a timely basis, if at all; and any of
Sarepta's drug candidates may fail in development, may not receive
required regulatory approvals, or be delayed to a point where they do
not become commercially viable.  
Any of the foregoing risks could materially and adversely affect
Sarepta's business, results of operations and the trading price of
Saretpa's common stock. For a detailed description of risks and
uncertainties Sarepta faces, you are encouraged to review the
official corporate documents filed with the Securities and Exchange
Commission. Sarepta does not undertake any obligation to publicly
update its forward-looking statements based on events or
circumstances after the date hereof. 
Sarepta Investor and Media Contact: 
Erin Cox
Press spacebar to pause and continue. Press esc to stop.